Dec 20, 2023
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Dec 07, 2023
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
Nov 22, 2023
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
Nov 09, 2023
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Nov 06, 2023
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
